Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Southern Energy Corp. Completes US$23.5 Million Financings and Royalty Sale (click to learn more) Cariboo Gold History Inspires Modern Discovery (CSE:GCC) (OTC:GCCFF) (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Celldex Therapeutics Inc CLDX

Healthcare Biotechnology
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CLDX)

Celldex to Present at Upcoming Investor Conferences

GlobeNewswire 8 days ago

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

GlobeNewswire December 9, 2025

Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 10, 2025

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

GlobeNewswire November 10, 2025

Celldex to Present at Upcoming Investor Conferences

GlobeNewswire November 7, 2025

Celldex Presents Additional Positive Data Demonstrating Barzolvolimab's Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study

GlobeNewswire November 6, 2025

Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20

GlobeNewswire November 6, 2025

Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition

GlobeNewswire October 30, 2025

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

GlobeNewswire September 17, 2025
View More News ››

Opinion & Analysis (NDAQ:CLDX)

Investing in biotech stocks is not for amateurs (CLDX) (NPSP)

Marc Lichtenfeld January 17, 2014

Big money to be made in biotech stocks

Andrew Mickey December 1, 2008

Dividend and speculative stock picks

J.W. Cotton October 28, 2008
View More Opinion ››

Bullboard Posts (NDAQ:CLDX)

Woo-ho

Finally, a rally, a trend change, and the company coming back to life...!
paths - June 17, 2020

it's a sell today for me

at.$3.27 per share,it's been over a year for me with this one and it's time to take my profits out.
coolfooldumbguy - February 21, 2020

this stock

should do well this year for me,so glta shareholders buying it at these low prices.
coolfooldumbguy - February 18, 2019

forming a head & shoulders pattern

which is a really good chart for this one,so glta.
coolfooldumbguy - February 6, 2019

climb up starts today for me

so glta shareholders.
coolfooldumbguy - January 2, 2019

added more of this one

at these low prices,averaging my costs down,so glta.
coolfooldumbguy - December 7, 2018
View more Bullboard ››

Viridian Metals Inc.

Viridian Metals Inc.

Viridian Metals Inc. is a Canadian company engaged in generative exploration for critical metals, with a primary focus on ...
View More »

Podcasts